NSRX · Nasus Pharma Ltd
$3.09
+0.02 (+0.65%)
At close · Jul 27
Market Cap
$36.54M
Shares
11.71M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.09
Open$3.08
Day$2.96–3.10
52W$1.98–9.99
Avg vol 30d17K
Short int171K · 1.5% float · 11.8d
Short vol23%
DataAug 2025–Jul 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.66
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−38%
below
Price vs 50-day avg
−0%
below
RSI (14)
49
neutral
MACD trend
Negative
52-week position
14%
near low
Momentum
relative strength
1-month return
−6%
trailing
6-month return
−46%
trailing
YTD return
−66%
this year
Relative strength
−53%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+350% holders QoQ · +7 funds added
Insider flow
Accumulating
Net +$20.3K over 90 days · 0% sells
Short interest
Falling
1.46% of float · ▼ -0.9% MoM · 11.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
9 holders — 13F breadth
Squeeze score
51
elevated · 0–100
Fundamentals
EPS growth
−227%
Y/Y
Free cash flow
$-4.9M
Balance sheet
$1.2M
net cash
Quant / Vol
risk profile
Volatility
103%
annualized · 1-yr
Max drawdown
−78%
past year
ATR
6.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−38%
Bearish
Price vs 50-day avg
−0%
Neutral
RSI (14)
49
Neutral
MACD trend
Negative
Bearish
52-week position
14%
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $3 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+350% holders QoQ · +7 funds added
Insider flow
Accumulating
Net +$20.3K over 90 days · 0% sells
Short interest
Falling
1.46% of float · ▼ -0.9% MoM · 11.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
9 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $2
Now $3 · 14%
52-wk high $10
vs 200-day avg -38%
vs 50-day avg 0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NSRX
this stock
Nasus Pharma Ltd
|
$36.54M | -66.2% | — | — | 1.5% |
|
LLY
ELI LILLY & Co
|
$1.13T | +11.6% | +44.7% | 42.5 | 1.1% |
|
JNJ
Johnson & Johnson
|
$634.77B | +29.2% | +6.0% | 30.6 | 1.1% |
|
ABBV
AbbVie Inc.
|
$458.24B | +13.3% | +8.6% | 127.8 | 1.3% |
|
MRK
Merck & Co., Inc.
|
$323.72B | +26.0% | +1.4% | 36.9 | 1.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
9
- % held
- 18.6%
- Net QoQ
- +2.2M sh
- Top holder
- Balyasny Asset Management…
Held
Float
Short & Settlement
Smart Money
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NSRX | +2.7% | -6.4% | -46.2% | -11.7% | -66.2% |
| SPY | -0.6% | +0.7% | +6.8% | -1.0% | +8.4% |
| vs SPY | +3.2% | -7.0% | -53.0% | -10.7% | -74.6% |